University of Minnesota/Masonic Cancer Center

Minneapolis, MN

Description

The Division of Pediatric Hematology/Oncology has been actively engaged in childhood cancer research and treatment for several decades. Since 1998, the Masonic Cancer Center (MCC) at the UMN has been an NCI-Designated Comprehensive Cancer Center. In 2008, the MCC formalized existing cross-departmental collaborations and partnerships through the creation of a Brain Tumor Program Translational Working Group. Translational Working Groups within the MCC are a mechanism to foster interprogrammatic and translational research to promote new discoveries in specific cancers, one of the primary foci being childhood brain tumors. The Brain Tumor Program, which is led by the Department of Pediatrics, accelerates the flow of information from basic science to the discovery of safer and more effective therapies for central nervous system (CNS) tumors. In total, 47 researchers, whose research spans the continuum of scientific research, are a part of the Brain Tumor Program. Given the excellent support of the MCC, these researchers are translating pre-clinical findings into clinical trials conducted here and at other instiutions.

Contact information

 

2450 Riverside Avenue
Minneapolis, MN 55454

Phone: 612-626-2778

Team

Principal Investigator
Pediatric Neuro-oncologist
Dr. Moertel graduated from the University of Minnesota Medical School. He completed his internship and residency in Pediatrics at the Baylor College of Medicine in Houston, Texas. He then completed his fellowship in Pediatric Hematology and Oncology at the Mayo Clinic/ Mayo Graduate School of Medicine in Rochester, Minnesota. He joined the medical staff at Children's Hospitals and Clinics of Minnesota in 1990. While at Children's, he served as Chief of Staff, Medical Director of Hematology/Oncology and Lead Physician in the Theodora Lang Oncology Clinic, among other leadership positions. Since his arrival at the University of Minnesota, he has specialized exclusively in the care of children and young adults with brain tumors and is the leader of the Neurofibromatosis comprehensive clinic. He has led important clinical trials employing immunotherapy to fight malignant brain tumors and works closely with the laboratory scientists at the University to develop new targeted therapies for patients with nervous system tumors.

Susan Weber, BS, CCRP

Site Coordinator

Ruth Elling, CCRP

Site Coordinator

Darlette Luke

Pharmacist

Tambra Dahlheimer, CNP

Registered Nurse

Jamie Walski, BA, CCRP

Research Manager

Renee Edelhauser

Site Coordinator